In this trial, the GH dose of 5 mg/day subcutaneously for 1 week, followed by 1.5 mg/day maintenance dose for 4 months was superior to placebo with regard to reducing Crohn's disease activity index (CDAI)[7] by a mean of 143 ± 144 and 19 ± 63, respectively.[8]. The gene discussed is GH1; the disease is Crohn disease.